Parkinson Disease Management: From First Prescription to Advanced Therapy
Clinical Practice Update — Levodopa Initiation, Dopamine Agonist Safety, Motor Fluctuations, Deep Brain Stimulation, and Non-Motor Symptom Management in Adults
This is an original clinical education article informed by current guidelines and evidence. See References below for source documents.
- Clinical Focus
- Initial dopaminergic therapy selection (levodopa vs dopamine agonists vs MAO-B inhibitors), managing motor fluctuations and dyskinesia, advanced therapies (DBS, infusion therapies), and non-motor symptom management
- Target Audience
- Neurologists, movement disorder specialists, general physicians managing PD, geriatricians, PD nurses, pharmacists
- Setting
- Neurology clinics, movement disorder centres, primary care, geriatric medicine
- Source Evidence
- •AAN 2021 Guideline — Dopaminergic Therapy for Motor Symptoms in Early PD (reaffirmed February 2025)
- •MDS 2025 Evidence-Based Medicine Review — Treatments for PD Motor Fluctuations
- •EAN/MDS-ES 2022 Guideline — Invasive Therapies in PD
- •NICE NG71 (2017, updated February 2025) — Parkinson’s Disease in Adults
- •LEAP Trial Long-Term Follow-Up (Frequin et al., Mov Disord 2024)
Key Clinical Takeaways
- 1Levodopa is the initial preferential dopaminergic therapy for motor symptoms in early PD — it provides superior motor benefit compared to dopamine agonists at 1–5 years of follow-up → Early PD
- 2Do not prescribe dopamine agonists to patients over 70 years, or to those with a history of impulse control disorders, pre-existing cognitive impairment, excessive daytime somnolence, or hallucinations → Drug Safety
- 3Start with immediate-release levodopa rather than controlled-release or levodopa/carbidopa/entacapone combinations in early disease — no formulation has shown superior efficacy in this setting → Early PD
- 4Delaying levodopa does not delay motor complications — the LEAP trial confirmed no disease-modifying effect from early vs delayed initiation; prescribe the lowest effective dose that provides symptomatic benefit → LEAP Trial
- 5MAO-B inhibitors (rasagiline, selegiline, safinamide) may be considered as initial therapy for mild motor symptoms, but patients should be counselled that levodopa provides greater motor benefit → Early PD
- 6For motor fluctuations on levodopa, the MDS 2025 review rates pramipexole, ropinirole, rotigotine, opicapone, safinamide, levodopa ER, and bilateral STN-DBS as efficacious treatments → Motor Fluctuations
- 7Consider bilateral STN-DBS for patients with levodopa-responsive motor fluctuations who have a good preoperative levodopa response (≥50% improvement), normal cognition, and no uncontrolled psychiatric disease → Advanced Therapy
- 8Screen all patients on dopamine agonists for impulse control disorders (pathological gambling, hypersexuality, compulsive shopping, binge eating) at every visit — taper or discontinue if ICDs develop → Drug Safety
- 9For PD psychosis, use clozapine (first-line per NICE) or pimavanserin (FDA-approved); quetiapine may be considered off-label. Never use typical antipsychotics or olanzapine — they worsen parkinsonism → Non-Motor
- 10Rivastigmine is the only cholinesterase inhibitor with RCT evidence for PD dementia; consider it when cognitive decline impairs function → Non-Motor
How Should You Initiate Dopaminergic Therapy in Early PD?
The AAN 2021 guideline (reaffirmed February 2025) provides the most current evidence-based framework for initial dopaminergic therapy. Its central message is clear: levodopa provides greater motor benefit than dopamine agonists or MAO-B inhibitors and should be recommended as the initial preferential therapy. The longstanding fear of “levodopa toxicity” or that early use accelerates motor complications has been disproved by the LEAP trial.
Recommend levodopa as the initial preferential dopaminergic therapy for patients with early PD who seek treatment for motor symptoms. Use the lowest effective dose. Prescribe immediate-release carbidopa/levodopa rather than controlled-release or levodopa/carbidopa/entacapone in early disease.
Strong Rec Moderate Evidence AAN 2021Avoid prescribing dopamine agonists to patients at higher risk of adverse effects: individuals over 70 years of age, and those with a history of impulse control disorders (ICDs), pre-existing cognitive impairment, excessive daytime somnolence (EDS), or hallucinations.
Strong Rec Moderate Evidence AAN 2021Consider prescribing a MAO-B inhibitor (rasagiline, selegiline) as initial therapy for patients with mild motor symptoms who wish to delay levodopa. Counsel that levodopa provides greater motor benefit and that over 60% of patients started on MAO-B monotherapy will ultimately require levodopa.
Conditional Rec Low Evidence AAN 2021Monitor patients on dopamine agonists for impulse control disorders at every visit. If ICDs develop, taper or discontinue the agonist. Monitor for dopamine agonist withdrawal syndrome (DAWS) during dose reduction — use gradual staged tapering.
Strong Rec Moderate Evidence AAN 2021How Should You Manage Motor Fluctuations?
Motor fluctuations (wearing-off, on-off phenomena, freezing) develop in approximately 40–50% of patients within 5 years of levodopa initiation. The MDS 2025 EBM review provides the most current assessment of treatment efficacy for motor fluctuations.
Treatments for Motor Fluctuations: MDS 2025 Evidence-Based Ratings
| MDS 2025 Rating | Oral / Transdermal Adjuncts | Surgical / Device-Aided |
|---|---|---|
| Efficacious | Levodopa ER, pramipexole (IR & ER), ropinirole IR, rotigotine, opicapone, safinamide | Bilateral STN-DBS |
| Likely Efficacious | Entacapone, rasagiline, istradefylline, amantadine ER, zonisamide, ropinirole ER & patch | Continuous intestinal levodopa infusion (LCIG), continuous SC levodopa (foslevodopa-foscarbidopa), continuous SC apomorphine, bilateral GPi-DBS, pallidotomy |
- First-line approach: optimise levodopa dosing (fractionation, dose timing) before adding adjuncts.
- COMT inhibitors (opicapone preferred over entacapone for convenience and efficacy) extend levodopa duration.
- Amantadine ER is the only agent specifically efficacious for levodopa-induced dyskinesia.
- Tolcapone, pergolide, bromocriptine, and cabergoline are no longer recommended in the MDS 2025 review.
When Should You Refer for Advanced Therapy?
Consider referral for bilateral STN-DBS in patients with levodopa-responsive fluctuations and/or tremor when optimised oral therapy is insufficient. Prerequisites: good levodopa response (≥50% UPDRS improvement in on vs off medication test), normal cognition, no uncontrolled psychiatric disease, and adequate general health for surgery.
Strong Rec High Evidence EAN/MDS-ES 2022 MDS 2025Consider continuous infusion therapy (levodopa-carbidopa intestinal gel [LCIG], subcutaneous foslevodopa-foscarbidopa, or subcutaneous apomorphine) for patients with advanced motor fluctuations not responding to optimised oral treatment, particularly when DBS is not suitable (cognitive impairment, advanced age, patient preference).
Moderate Rec Moderate Evidence EAN/MDS-ES 2022 MDS 2025Clinical Decision Pathway
Evidence in Context
Levodopa vs Dopamine Agonists: What the Trials Show
The AAN 2021 systematic review found that levodopa provides superior motor benefit (UPDRS Part III improvement) compared to dopamine agonists at 1, 2, 4, and 5 years. Levodopa is more likely to cause dyskinesia (risk difference approximately 18.7% at 2 years, 29.2% at 4 years), but severe or disabling dyskinesia is rare during the first 5 years. Dopamine agonists carry higher risks of impulse control disorders, hallucinations, excessive daytime somnolence, and sudden-onset sleep. No dopamine agonist formulation (oral, transdermal, or injection) has been shown to be clearly superior to another.
Managing Non-Motor Symptoms
PD Dementia: Rivastigmine (oral or transdermal) is the only cholinesterase inhibitor with Level A evidence for PD dementia. NICE NG71 also permits off-label use of donepezil and galantamine. Memantine may be considered for those who cannot tolerate cholinesterase inhibitors.
PD Psychosis: First, reduce or eliminate anticholinergics, amantadine, and dopamine agonists if possible. For persistent psychosis, clozapine is recommended (NICE first-line, requires mandatory blood monitoring for agranulocytosis). Pimavanserin is FDA-approved for PD psychosis and does not worsen motor symptoms. Quetiapine is commonly used off-label but has weaker evidence. Never use olanzapine, risperidone, or typical antipsychotics.
Depression: SSRIs and SNRIs may be used. Pramipexole has shown antidepressant effects in PD. NICE recommends CBT as part of management.
Orthostatic hypotension: Reduce or eliminate causative medications first. Consider fludrocortisone (off-label) or midodrine/droxidopa as pharmacological options.
REM sleep behaviour disorder: Clonazepam or melatonin (both off-label per NICE NG71) may be considered.
What We Still Don’t Know
Disease modification: No therapy has been proven to slow or halt PD progression. Alpha-synuclein-targeting antibodies (prasinezumab, cinpanemab) and GLP-1 receptor agonists (lixisenatide, exenatide) are in clinical trials but results have been mixed or preliminary.
Optimal DBS timing: Whether earlier DBS (before significant disability accumulation) improves long-term outcomes remains uncertain. The EARLYSTIM trial suggested benefit in earlier intervention, but patient selection criteria differ from routine practice.
Continuous SC levodopa: Foslevodopa-foscarbidopa (subcutaneous levodopa pump) is a newer option but requires longer-term follow-up data on tolerability, as the initial phase 3 trial showed approximately 30% dropout in the active arm over 12 weeks.
MRgFUS role in PD: MRI-guided focused ultrasound thalamotomy is approved for tremor-dominant PD in some countries, but the EAN/MDS-ES 2022 guideline recommends it only within registries due to limited long-term data and absence of evidence for off-time reduction.
References
- 1.Pringsheim T, Day GS, Smith DB, et al. Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary. Neurology. 2021;97(20):942–957. doi:10.1212/WNL.0000000000012868
- 2.de Bie RMA, Katzenschlager R, Swinnen BEKS, et al. Update on Treatments for Parkinson’s Disease Motor Fluctuations — An International Parkinson and Movement Disorder Society Evidence-Based Medicine Review. Mov Disord. 2025. doi:10.1002/mds.30162
- 3.Deuschl G, Antonini A, Costa J, et al. European Academy of Neurology/Movement Disorder Society–European Section Guideline on the Treatment of Parkinson’s Disease: I. Invasive Therapies. Eur J Neurol. 2022;29(9):2580–2595. doi:10.1111/ene.15386
- 4.National Institute for Health and Care Excellence. Parkinson’s Disease in Adults. NICE Guideline NG71. Published July 2017, last updated February 2025. nice.org.uk/guidance/ng71
- 5.Frequin HL, Verschuur CVM, Suwijn SR, et al. Long-Term Follow-Up of the LEAP Study: Early Versus Delayed Levodopa in Early Parkinson’s Disease. Mov Disord. 2024;39(6):975–982. doi:10.1002/mds.29796
How to Read the Evidence Tags
Every recommendation carries two tags. These are Medaptly’s own simplified interpretations.
Recommendation Strength
| Tag | Meaning | In Practice |
|---|---|---|
| Strong Rec | Benefits clearly outweigh risks. | Standard practice. |
| Moderate Rec | Evidence favours benefit; some uncertainty. | Most patients should receive this. |
| Conditional Rec | Benefit less certain; individualise. | Shared decision-making. |
| Against | No benefit or risks outweigh benefits. | Avoid. |
Evidence Quality
| Tag | Meaning | Confidence |
|---|---|---|
| High Evidence | Multiple RCTs or meta-analyses. | Very confident. |
| Moderate Evidence | Single RCT or large observational studies. | Reasonably confident. |
| Low Evidence | Expert consensus or small studies. | Less certain. |
These are Medaptly’s simplified interpretations. For full classification systems, consult the original documents in References.